Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis

Ähnliche Einträge

• Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
  von: Angela E. Alnemri, et al.
  Veröffentlicht: (2024)
• Notch signaling genes and CD8+ T‐cell dynamics: Their contribution to immune‐checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective study
  von: Kazuhiro Ogi, et al.
  Veröffentlicht: (2024)
• Early recurrence, time‐to‐recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M‐HNSCC) patients treated with first line platinum‐based chemotherapy
  von: Pasvich Pitakpaiboonkul, et al.
  Veröffentlicht: (2024)
• A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ALARM” study
  von: Sofia Agelaki, et al.
  Veröffentlicht: (2024)
• Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study
  von: Takahiro Inoue, et al.
  Veröffentlicht: (2026)